Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety

•In comparison to the previous meta-analysis, our study not only confirmed that tocilizumab can effectively reduce the ARR ratio of NMOSD patients but also can significantly improve patients’ clinical disability.•Tocilizumab's efficacy in reducing the ARR ratio in patients with NMOSD is related...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis and related disorders 2023-12, Vol.80, p.105062-105062, Article 105062
Hauptverfasser:	Wang, Yupeng, Zhao, Mengchao, Yao, Mengyuan, Yang, Zhaohong, Li, Bo, Yin, Linlin, Geng, Xingchao
Format:	Artikel
Sprache:	eng
Schlagworte:	Annualized relapse rate Antibodies, Monoclonal, Humanized - adverse effects Aquaporin 4 Disability Evaluation Expanded disability status scale Female Humans Immunoglobulin G Male Meta-analysis Neuromyelitis Optica - drug therapy Neuromyelitis optica spectrum disorders Systematic review Tocilizumab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!